Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UGCKA
ADC Name
C12G1-DM1
Synonyms
C12G1-SMCC-DM1
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Investigative
Drug-to-Antibody Ratio
5.07
Structure
Antibody Name
Anti-NECTIN2 mAb c12G1
  Antibody Info 
Antigen Name
Nectin-2 (NECTIN2)
  Antigen Info 
Payload Name
Mertansine DM1
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Emtansine
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 9 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 0
%
SK-OV-3 cells
Ovarian serous cystadenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 0
%
SK-OV-3 cells
Ovarian serous cystadenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 10.4
%
SK-OV-3 cells
Ovarian serous cystadenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 11.5
%
Ovarian cancer cells
Ovarian cancer
Tumor Growth Inhibition value (TGI) 
≈ 19.6
%
Ovarian cancer cells
Ovarian cancer
Tumor Growth Inhibition value (TGI) 
≈ 32.9
%
OV-90 cells
Ovarian adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 46.4
%
Ovarian cancer cells
Ovarian cancer
Tumor Growth Inhibition value (TGI) 
≈ 84.4
%
OV-90 cells
Ovarian adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 88.9
%
OV-90 cells
Ovarian adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 9 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous cystadenocarcinoma SK-OV-3 cells CVCL_0532
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 0.00% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous cystadenocarcinoma SK-OV-3 cells CVCL_0532
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 10.40% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian serous cystadenocarcinoma SK-OV-3 cells CVCL_0532
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 11.50% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian cancer Ovarian cancer cells Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 19.60% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian cancer Ovarian cancer cells Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 32.90% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 1 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 46.40% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian cancer Ovarian cancer cells Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 84.40% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 3 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
Experiment 9 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 88.90% (Day 30) High NECTIN2 expression (NECTIN2+++)
Method Description
Treatments c12G1-DM1 at 5 mg/kg every 4th day by intraperitoneal injection.
In Vivo Model Ovarian cancer CDX model
In Vitro Model Ovarian adenocarcinoma OV-90 cells CVCL_3768
References
Ref 1 A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models. Int J Mol Sci. 2022 Oct 15;23(20):12358.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.